Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for serious neurological, autoimmune and rare diseases. Founded in 1978, our work in biologics and small-molecule drug discovery has led to the world’s most extensive portfolio of multiple sclerosis therapies and innovative new treatments for hemophilia patients.
Our experience, capabilities and passion for innovation have enabled us to build a pipeline and develop advanced research programs that include exploration of potential candidates for serious and difficult-to-treat diseases including Alzheimer’s disease, MS, spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), and neuropathic pain.
We are committed to research that uncovers the underlying biology of complex diseases. Our focus is on illnesses with few, if any, treatment options. Biogen’s success will always be measured by the answer to a simple question: Have we truly made a difference in the lives of patients?